合并与不合并基础疾病的急性呼吸窘迫综合征患者的管理与结局
该研究纳入1997至2014年间19个ICU收治的4953例ARDS患者,按是否合并重大基础疾病分组,采用分层于中心的多变量Cox分析识别第28天死亡的决定因素。51.4%的患者合并重大基础疾病,且该比例在2008年后增加;合并血液系统恶性肿瘤与重度ARDS及难治性低氧血症的挽救治疗相关,COPD、HIV感染和血液系统恶性肿瘤与入院当天接受有创机械通气的可能性较低相关。合并重大基础疾病者入院当天SOFA评分更高,更常接受血管升压药、透析或治疗限制决策。第28天总死亡率为33.7%,无重大基础疾病者为27.2%,合并重大基础疾病者从COPD的31.1%至血液系统恶性肿瘤的56%。多变量分析显示COPD患者死亡率较低,慢性心力衰竭、实体瘤或血液系统恶性肿瘤患者死亡率较高。
要点
- 4953例ARDS患者中2545例(51.4%)合并重大基础疾病,该比例在2008年后增加。
- 第28天死亡率总体33.7%,无重大基础疾病者27.2%,合并重大基础疾病者从COPD的31.1%至血液系统恶性肿瘤的56%。
- 多变量分析显示COPD患者死亡率较低,慢性心力衰竭、实体瘤或血液系统恶性肿瘤患者死亡率较高。
- 合并重大基础疾病者入院当天SOFA评分更高,更常接受血管升压药、透析或治疗限制决策。
- 血液系统恶性肿瘤与重度ARDS及难治性低氧血症的挽救治疗相关。
适用人群与场景
- 1997至2014年间入住19个ICU的ARDS患者,共4953例。
- 按是否合并重大基础疾病分组,合并重大基础疾病者2545例(51.4%)。
研究设计与关键结果
- 研究类型为多中心队列研究,纳入19个ICU的4953例ARDS患者,按基础疾病分组,采用分层于中心的多变量Cox分析识别第28天死亡的决定因素。
- 第28天死亡率总体33.7%,无重大基础疾病者27.2%,合并重大基础疾病者从COPD的31.1%至血液系统恶性肿瘤的56%。
- 多变量分析显示COPD患者死亡率较低,慢性心力衰竭、实体瘤或血液系统恶性肿瘤患者死亡率较高。
- 合并重大基础疾病者入院当天SOFA评分更高,更常接受血管升压药、透析或治疗限制决策。
- 血液系统恶性肿瘤与重度ARDS及难治性低氧血症的挽救治疗相关;COPD、HIV感染和血液系统恶性肿瘤与入院当天接受有创机械通气的可能性较低相关。
- 死亡率独立关联于第1天PaO2/FiO2和PaCO2、肺源性ARDS、更差的SOFA评分及ICU获得性事件。
证据类型、等级与局限
- 证据类型:多中心队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,这些发现不支持将合并严重基础疾病的ARDS患者排除于随机临床试验之外;无论合并何种基础疾病,均需开展ARDS试验。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
RATIONALE: The standard of care for patients with acute respiratory distress syndrome (ARDS) has been developed based on studies that usually excluded patients with major comorbidities.
OBJECTIVES: To describe treatments and outcomes according to comorbidities in patients with ARDS admitted to 19 ICUs (1997-2014).
METHODS: Patients were grouped based on comorbidities. Determinants of day-28 mortality were identified by multivariable Cox analysis stratified on center.
MEASUREMENTS AND MAIN RESULTS: Among 4953 ARDS patients, 2545 (51.4%) had major comorbidities; the proportion with major comorbidities increased after 2008. Hematological malignancy was associated with severe ARDS and rescue therapies for refractory hypoxemia. COPD, HIV infection, and hematological malignancy were associated with a lower likelihood of invasive mechanical ventilation on the admission day. Admission-day SOFA score was higher in patients with major comorbidities, who more often received vasopressors, dialysis, or treatment-limitation decisions. Day-28 mortality was 33.7% overall, 27.2% in patients without major comorbidities, and 31.1% (COPD) to 56% (hematological malignancy) in patients with major comorbidities. By multivariable analysis, mortality was lower in patients with COPD and higher in those with chronic heart failure, solid tumors, or hematological malignancies. Mortality was independently associated with PaO2/FiO2 and PaCO2 on day 1, ARDS of pulmonary origin, worse SOFA score, and ICU-acquired events.
CONCLUSIONS: Half the patients with ARDS had major comorbidities, which were associated with severe ARDS, multiple organ dysfunction, and day-28 mortality. These findings do not support the exclusion of ARDS patients with severe comorbidities from randomized clinical trials. Trials in ARDS patients with whatever comorbidities are warranted.
参考来源
- Azoulay E, Lemiale V, Mourvillier B, et al. Management and outcomes of acute respiratory distress syndrome patients with and without comorbid conditions. Intensive Care Med. 2018. PMID: 29881987. doi:10.1007/s00134-018-5209-6
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。